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Abstract
Objectives—Patients with inflammatory bowel disease (IBD) may be at increased risk for
pneumocystis jiroveci pneumonia (PCP). Our aims were 1) to determine the incidence and relative
risk of PCP in IBD and 2) to describe medication exposures in IBD patients with PCP.
Methods—We performed a retrospective cohort study and a case series using administrative data
from IMS Health Inc, LifeLink™ Health Plan Claims Database. In the cohort, IBD patients were
matched to 4 individuals with no IBD claims. PCP risk was evaluated by incidence rate ratio
(IRR) and adjusted Cox proportional hazards modeling. The demographics and medication
histories of the 38 cases of PCP in IBD patients were extracted.
Results—The cohort included 50,932 patients with CD, 56,403 patients with UC, and 1269 with
unspecified IBD; matched to 434,416 individuals without IBD. The crude incidence of PCP was
higher in the IBD cohort (10.6/100,000) than in the non-IBD cohort (3.0/100,000). In adjusted
analyses, PCP risk was higher in the IBD vs. non-IBD cohort (HR 2.96, 95% CI 1.75–4.29), with
the greatest risk in Crohn’s disease (CD) as compared to non-IBD (HR 4.01, 95% CI 1.88–8.56).
In the IBD case series of PCP cases (n=38), the median age was 49 (IQR 43–57). A total of 20
(53%) were on corticosteroids alone or in combination with other immunosuppression.
Conclusions—Although the overall incidence of PCP is low, patients with IBD are at increased
risk. IBD patients with PCP are predominantly on corticosteroids alone or in combination prior to
PCP diagnosis.
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Patients with inflammatory bowel disease (IBD), particularly those treated with
immunosuppressive agents, are at risk of infectious complications. In fact, infections are
among the most common causes of death in patients with IBD, particularly respiratory
infections.1 Case reports have described cases of pneumocystis jiroveci pneumonia
(formerly known as pneumocystis carinii or PCP) associated with various forms of
immunosuppression commonly used in IBD, including azathioprine, corticosteroids,
cyclosporine and infliximab.2–7
PCP is an atypical unicellular fungus that produces alveolar infiltrates and local
inflammatory reactions which widen the alveolar- arterial oxygen gradient.8, 9. PCP is
associated with high rates of morbidity and mortality given its profound effects on gas
exchange. PCP is typically associated with human immunodeficiency virus (HIV) and is
among the most common acquired immunodeficiency syndrome (AIDS) defining
illnesses.10 Its progression in the HIV population is slow and indolent characterized by
fever, cough and pulmonary infiltrates whereas a more aggressive course is seen in the non-
HIV population likely secondary to a more intense inflammatory response that can
culminate in respiratory failure. In the HIV population, patients with a CD-4 lymphocyte
count of <200 cells/mm3 are placed on PCP prophylaxis with an agent such as
trimethoprim-sulfamethoxazole (TMP-SMX). There is current debate, without consensus
guidelines, as to whether prophylaxis against PCP is warranted in patients with IBD on
immunosuppression.9 This highlights the need for additional data on the overall incidence
and medication-specific risk factors for PCP in the IBD population.
Therefore, we aimed to determine the risk of PCP in patients with IBD as compared to a
non-IBD comparison cohort without HIV. We also aimed to describe the medication
exposures in patients with IBD and PCP.
Material and Methods
We analyzed the procedural and outpatient pharmaceutical insurance claims contained in the
LifeLink™ Health Plan Claims Database (IMS Health Inc, Norwalk, CT) for the period
January 1, 1997 through December 31, 2009. This longitudinal, patient-level database has
been used in previous epidemiologic studies of IBD.11, 12 The source database contains
enrollment information on over 60 million persons from over 98 health plans across the U.S.
The included health care plans capture a geographically diverse sample from across the
United States. Only health plans that submit data for all members are included in the
database, ensuring complete data capture and representative samples. Prior studies have
reported the IMS Health database to be representative of the national commercially insured
population on a variety of demographic measures.13
Study Design
We performed a retrospective cohort study to determine the overall risk of PCP in IBD
patients compared with a non-IBD matched comparison cohort. We then described a case
series to determine medication exposures prior to PCP in patients with IBD. A similar
retrospective cohort design has previously been used by our group11 and also by Gupta et
al14 to evaluate the incidence and risk of infections and malignancies in patients with IBD.
Cohort Study
Patient selection—All patients aged <64 years with at least 12 months of continuous
health plan enrollment were eligible for inclusion in this analysis. We chose 64 as the upper
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age limit to avoid the possibility of missing data resulting from Medicare dual eligibility
(which begins at age 65). Individuals were also required to have ongoing pharmacy
coverage with their health plan in order to fully capture medication exposures. We identified
cases of Crohn’s disease (CD) and ulcerative colitis (UC) by using a previously reported
administrative definition expanded to include updated medications recently approved for
IBD indications.15 The precise definition included patients with at least 3 health care
contacts, on different days, associated with an International Classification of Diseases, 9th
Revision, Clinical Modification (ICD-9) diagnosis code for CD (555.xx) or UC (556.xx), or
patients with at least 1 claim for CD or UC and at least 1 pharmacy claim for any of the
following medications: mesalamine, olsalazine, balsalazide, sulfasalazine, 6-
mercaptopurine, azathioprine, methotrexate, infliximab, adalimumab, certolizumab pegol,
natalizumab and enteral budesonide. For patients who had claims for both CD and UC,
disease assignment was made according to the majority of the last 9 claims or the majority
of total claims if there were fewer than 9. We matched each IBD patient to 4 non-IBD
subjects by age, gender, U.S. census region and date of health plan coverage. All individuals
with any ICD-9 code for human immunodeficiency virus (HIV) (042–044.9) were excluded
related to inherent differences in susceptibility to infections.
Cohort lead time and follow-up—For each IBD patient, follow-up began six months
after health plan enrollment or on the date of the first claim with a diagnosis code for IBD,
whichever came later. For members of the non-IBD comparison cohort, follow up began on
the same calendar day as the IBD patient to whom they were matched. A minimum of six
months of health plan enrollment was required prior to matching. Thus, each individual had
a six month “screening period” immediately preceding cohort entry during which healthcare
utilization, comorbidities, and other covariates were assessed. Individuals with a PCP claim
in the last month of screening time were excluded, as this was considered to represent a
prevalent diagnosis. Each member of the cohort was followed until the first diagnosis of
PCP, or, if none, until censoring at the earlier of one of two events: discontinuation of
primary or pharmacy insurance coverage, or age > 64.
Assessment of outcome (PCP)—PCP was defined as either 1) an inpatient
hospitalization with an ICD-9 code for pneumocystis (136.3), or 2) an outpatient visit with a
ICD-9 code for PCP combined with an outpatient prescription for a PCP-specific antibiotic
(TMP-SMX, atovaquone, dapsone, pentamidine, and primaquine) filled within 1 week
before or after the visit.
Assessment of exposures—We assessed each exposure during the screening period six
months prior to the start of follow-up. Health care utilization was estimated in a continuous
fashion by the total number of days with at least one health care contact. Utilization has been
measured in this fashion in prior pharmacoepidemiology studies.16 Comorbidities were
assessed using the Quan update17 of the validated Deyo comorbidity index for
administrative data.18 Medication use, including immunosuppressive and biologic
medications was assessed in an any/none fashion.
Statistical analysis—We used descriptive statistics to summarize characteristics of
patients with and without IBD. Continuous variables are reported as mean +/− standard
deviation or median and interquartile range (IQR), and categorical variables are reported as
percentages. We then calculated incidence rates of PCP (per 100,000 person-years) and used
incidence rate ratios (IRRs) and 95% confidence intervals (CIs) to compare the incidence of
PCP in IBD and non-IBD patients. We also performed subsequent analyses, stratifying by
age (in decades), and disease type (UC vs CD). We assessed for possible violation of the
proportional hazards assumption via log-log plots. As the assumption was not violated, we
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used Cox proportional hazards models to calculate hazard ratios (HRs) and 95% CIs for the
risk of pneumonia in the IBD cohort as compared to the non-IBD cohort, controlling for
health care utilization and comorbidities. Analyses were repeated stratified by CD versus
UC.
Descriptive Case Series
We next conducted a case-only study of the IBD patients with PCP. We extracted all data,
including outpatient medication exposures and hospitalizations, in the 60 days prior to PCP
diagnosis. This time frame was chosen in order to capture all immunosuppressive
medication therapy that could have an impact on PCP risk. Prior studies of infectious risks
in IBD have focused upon a 30 day time frame,14 this was increased to 60 days for the
current study in order to completely capture anti-TNF use, which could have been dosed up
to 60 days prior to the outcome.
Assessment of exposures
Outpatient Medication Use—The primary medications evaluated included azathioprine
and 6-mercaptopurine (thiopurine class), methotrexate, tacrolimus and cyclosporine
(calcineurin class), infliximab, adalimumab, certolizumab pegol and natalizumab (biologic
class), mycophenolate mofetil, and corticosteroids. Medication exposures were analyzed in
the 60 days prior to PCP diagnosis.
Hospitalization—Claims data do not contain information on inpatient medication use, as
these charges are packaged into the facility claims. Therefore, we have also evaluated
periods of hospitalization in the 60 days prior to PCP diagnosis, as we are unable to assess
medication use during these periods.
Statistical analysis
Characteristics of IBD patients with PCP were described using descriptive statistics,
including percentages of cases associated with particular classes of medications.
For all analyses, p values were two-sided, and a p value of .05 or less was considered
statistically significant. All statistical analyses were performed by using Stata version 10.0
(College Station, TX). The study protocol was granted exemption from review by the
Institutional Review Board at University of North Carolina because it involved the use of
existing, de-identified data.
Results
The cohort study population included 108,604 patients with IBD. Of these, 50,932 had CD,
56,403 had UC and 1269 had IBD with unknown type. There were a total of 434,416
individuals in the non-IBD comparison cohort. The median length of follow up within this
cohort was 24 months (IQR 12–42) with a range from 1–139 months. Length of follow-up
was similar for CD (34 months, IQR 19–51) and UC populations (36 months, IQR 21–54),
while significantly less in the non-IBD comparison cohort (21 months, IQR 10–38).
Characteristics of the patients with IBD as compared to the non-IBD cohort are shown in
table 1. Characteristics in general were similar, with increased health care utilization and
immunosuppressive medication use among the IBD patients, and among the CD as
compared to UC patients.
For patients with IBD, the overall annual incidence of PCP was 10.6/100,000, compared to
3.0/100,000 in the non-IBD cohort (figure 1). We also evaluated the incidence of PCP in the
IBD cohort, comparing those with any prescription for an immunosuppressive medication in
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the screening period to those without an immunosuppressive prescription. The incidence in
those with an immunosuppressive medication was higher at 32/100,000 person-years as
compared to 5.5/100,000 in those without. IBD patients had an increased risk of PCP (IRR
3.48, 95% CI 2.10–5.81). The risk was somewhat greater for CD as compared to non-IBD
(IRR 4.49, 95% CI 2.14–9.75) than for UC as compared to non-IBD (IRR 2.40, 95% CI
1.11–5.10). The incidence of PCP increased with age, with the highest incidence in the 60+
age strata 32.8/100,000. On adjusted Cox analysis, controlling for comorbidities and health
care utilization, the relative risk remained elevated in the overall IBD population (HR 2.96,
95% CI 1.75–4.29). Again, for CD the risk was somewhat greater (HR 4.01, 95% CI 1.88–
8.56) than for UC (HR 1.97, 95% CI 0.92–4.20).
In the case series, a total of 38 individuals with IBD developed PCP. The characteristics of
these individuals are shown in table 2. The median age was 49 (IQR 43–57) and gender was
roughly equal. Rates of comorbidities among IBD patients with PCP where fairly high,
particularly when compared to rates of comorbidities in the IBD population as a whole.
Utilization was also high among individuals with PCP. Figure 2 shows medications and
hospitalizations in the 60 days prior to PCP diagnosis among these 38 individuals with PCP.
A total of 20 (53%) were on corticosteroids alone or in combination with other
immunosuppressive medications. A total of 19 (50%) had a hospitalization in the 60 days
prior to PCP diagnosis. Only 5 (13%) had no outpatient medication prescriptions or
hospitalizations during this time period. In all, 21 (55.3%) were on immunosuppressive
drugs, 11 (28.9%) were on corticosteroids alone, 5 (13.2%) on combination thiopurine and
corticosteroid, 1 (2.6%) on thiopurine alone and 4 (10.5%) on corticosteroids and 2 other
immunosuppressive medications.
Discussion
In our cohort study, we demonstrated a markedly increased relative risk of PCP in patients
with IBD as compared to the general population, with an adjusted effect estimate of HR
2.96, 95% CI 1.75–4.29. However, the absolute risk remained quite low. The risk was higher
in the IBD cohort on immunosuppressive medications during screening (32/100,000) than
the IBD population on no immunosuppression during this time period (5.5/100,000).
Because these calculations incorporated medication use during the screening period, chronic
medications were more likely to be captured and corticosteroid use was likely
underrepresented. If PCP prophylaxis were 100% effective, and all individuals on any form
of immunosuppression were placed on prophylaxis, this would equate to a number needed to
treat (NNT) of 3750 to prevent 1 case of PCP in the IBD population. As there was the
possibility of underestimation of immunosuppressant exposure status, we recalculated the
NNT assuming 25, 50 and 75% underestimation of immunosuppressant exposure among the
PCP cases. The NNT remained quite high at 2952, 2432 and 2070 respectively, due to the
rarity of the outcome. Therefore, it is evident that other risk factors must also be taken into
consideration when targeting a population for prophylaxis. Also, these calculations are for
any immunosuppression, and the risk profile may differ in those on multiple
immunosuppressive agents. This is particularly important given the increased use of
combination immunosuppressive agents to treat certain patients with CD.
Our case series described medication and hospitalization risk factors in the 38 IBD patients
who developed PCP. In this group, the majority were on corticosteroids. Other
immunosuppressive medications were also common, as was hospitalization in the 60 days
preceding the diagnosis. Interestingly, rates of comorbidities were also high in this group of
individuals with IBD and PCP. The medication risk factors have been previously described
in case series in the IBD population,2–7 and also in the transplant population.
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The overall risk of PCP post solid organ transplant (SOT) has been estimated to be between
5 to 15% in the absence of PCP prophylaxis, with attack rates lowest after renal transplant
and highest in lung and heart transplant patients.19 The risk factors for PCP have been more
extensively studied in this population than the IBD population, likely because of the higher
incidence seen with the use of very potent immunosuppressive medications. Risk factors in
this population include high-dose corticosteroid therapy, malnutrition and post SOT
medications including antilymphocyte agents, calcineurin inhibitors, and biologic agents like
alemtuzumab.20, 21 These medications can cause severe neutropenia and lymphopenia,
which are believed to increase PCP risk. In addition, previous CMV infection, which has
been shown to have immunomodulatory effects; and underlying pulmonary disease, also
increase the risk of PCP in SOT patients.22, 23 As a result, post SOT, routine TMP-SMX
prophylaxis is recommended in most centers and is continued for at least the first 3 to 12
months, and in some situations for life.24, 25 Similar recommendations do not currently exist
in the IBD population. Data on risk of PCP in the IBD population currently consist of
descriptive series. Often, the individuals who develop PCP are on multiple
immunosuppressive agents.26
There are several strengths to this study of PCP in IBD. We were able to analyze a large
sample size. We also had considerable geographic diversity, with patients from all regions of
the US. By drawing from a large number of health plans of varying size, type, and location,
we believe these results to be broadly generalizable to the commercially insured US
population. We attempted to exclude individuals with known HIV, as this population is
known to have an increased risk of PCP. We obtained complete data on all billed outpatient
prescriptions in order to completely capture medication exposures; rather than relying on
patient recall. We were also able to account for health care utilization, as we had access to
all health care contacts within the database. Finally, we were able to account for
comorbidities through a validated comorbidity index for administrative data.17, 18
There are also several limitations to this study of administrative claims data. There is the
possibility of misclassification of exposure and outcome related to the lack of clinical detail.
We did use an IBD exposure definition previously used by our group11, 12 that requires
multiple health contacts and/or IBD related prescriptions. A similar, but even less specific,
administrative case definition has been validated by Herrinton et al.27 The Herrinton
definition was found to have a sensitivity exceeding 90% and a PPV exceeding 80% for
overall IBD. We used an outcome definition of PCP that required either inpatient claims
with an ICD-9 code specific for PCP or outpatient claims with this code in conjunction with
appropriate antibiotic dispensing. However, this definition has not been validated. Due to the
rarity of the outcome, there were relatively few overall cases of PCP. Another limitation to
this study is that the elderly and uninsured were not represented in our population; however,
this should not affect the internal validity of the relative risks (IRRs, HRs, ORs) for the
under 65 population. Further studies are needed to assess the risk of PCP among the elderly
and uninsured. As the risk of PCP increased with age, excluding patients 65 and over may
lead to an underestimation of the risk of PCP in this group of patients. While we had access
to all billed outpatient prescriptions, we did not have access to those medications given
during hospitalizations. As many immunosuppressive medications, such as corticosteroids,
are given during hospitalizations for IBD exacerbations, we could not specifically determine
medication risk factors in those with a hospitalization preceding their diagnosis of PCP.
There were too few cases to evaluate immunosuppression other than as an any/none
variable. The type and dose of immunosuppression may play a role in PCP risk, but we were
unable to assess this. Additionally, the case series may also have underestimated exposure to
medications prescribed more than 60 days prior to PCP diagnosis, for example 90 day
prescriptions or prednisone left over from prior prescriptions. Finally, we were unable to
account for certain exposures that may be related to the outcome, particularly smoking
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status. We were able to obtain data on chronic obstructive pulmonary disease (COPD),
which has been used as a proxy for smoking status in other studies using administrative data,
and controlled for this exposure in our analyses. In our study, COPD was more common
among CD patients than UC patients, consistent with prior reports in the literature of
increased smoking prevalence among those with CD. However, COPD was also more
common in both UC and CD patients as compared to the non-IBD cohort. COPD diagnosis
may therefore be a manifestation of both former and current smoking, as UC is often
diagnosed after smoking cessation.
In summary, we demonstrated an increased relative risk of PCP in patients with IBD.
However, the absolute risk remained quite low, even when considering only those on
immunosuppressive medications for IBD, and the NNT to prevent one case of PCP is
considerable. Moreover, there can be significant side effects with PCP prophylaxis,
including Stevens Johnson’s syndrome, methemoglobinemia, aplastic anemia and an
increased risk of pseudomembranous colitis. We therefore would not endorse global PCP
prophylaxis in IBD, but rather, consider prophylaxis on an individual basis. We found a
particularly increased risk with corticosteroids, prior hospitalization, and comorbid
conditions consistent with existing reports in the literature. Any targeted PCP prophylaxis
recommendations should consider these potential risk factors.
Acknowledgments
Grant support: This work was supported by a Career Development Award from the Crohn’s and Colitis Foundation
of America (MDL), NIH 1K08DK088957-01 (MDK), and NIH P30 DK34987 (RSS).
References
1. Hutfless SM, Weng X, Liu L, et al. Mortality by medication use among patients with inflammatory
bowel disease, 1996–2003. Gastroenterology. 2007; 133:1779–86. [PubMed: 18054550]
2. Khatchatourian M, Seaton TL. An unusual complication of immunosuppressive therapy in
inflammatory bowel disease. Am J Gastroenterol. 1997; 92:1558–60. [PubMed: 9317088]
3. Takenaka R, Okada H, Mizuno M, et al. Pneumocystis carinii pneumonia in patients with ulcerative
colitis. J Gastroenterol. 2004; 39:1114–5. [PubMed: 15580408]
4. Quan VA, Saunders BP, Hicks BH, et al. Cyclosporin treatment for ulcerative colitis complicated by
fatal Pneumocystis carinii pneumonia. BMJ. 1997; 314:363–4. [PubMed: 9040337]
5. Scott AM, Myers GA, Harms BA. Pneumocystis carinii pneumonia postrestorative proctocolectomy
for ulcerative colitis: a role for perioperative prophylaxis in the cyclosporine era? Report of a case
and review of the literature. Dis Colon Rectum. 1997; 40:973–6. [PubMed: 9269817]
6. Smith MB, Hanauer SB. Pneumocystis carinii pneumonia during cyclosporine therapy for ulcerative
colitis. N Engl J Med. 1992; 327:497–8. [PubMed: 1625744]
7. Kaur N, Mahl TC. Pneumocystis carinii pneumonia with oral candidiasis after infliximab therapy
for Crohn’s disease. Dig Dis Sci. 2004; 49:1458–60. [PubMed: 15481319]
8. Slifkin M, Doron S, Snydman DR. Viral prophylaxis in organ transplant patients. Drugs. 2004;
64:2763–92. [PubMed: 15563248]
9. Poppers DM, Scherl EJ. Prophylaxis against Pneumocystis pneumonia in patients with
inflammatory bowel disease: toward a standard of care. Inflamm Bowel Dis. 2008; 14:106–13.
[PubMed: 17886285]
10. Jones JL, Hanson DL, Dworkin MS, et al. Surveillance for AIDS-defining opportunistic illnesses,
1992–1997. MMWR CDC Surveill Summ. 1999; 48:1–22. [PubMed: 12412613]
11. Long MD, Herfarth HH, Pipkin CA, et al. Increased risk for non-melanoma skin cancer in patients
with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010; 8:268–74. [PubMed:
20005977]
12. Long MD, Porter CQ, Sandler RS, et al. Suboptimal rates of cervical testing among women with
inflammatory bowel disease. Clin Gastroenterol Hepatol. 2009; 7:549–53. [PubMed: 18996498]
Long et al. Page 7













13. Stempel DA, Mauskopf J, McLaughlin T, et al. Comparison of asthma costs in patients starting
fluticasone propionate compared to patients starting montelukast. Respir Med. 2001; 95:227–34.
[PubMed: 11266241]
14. Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with
inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006; 4:1483–90. [PubMed: 17162240]
15. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution
of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;
5:1424–9. [PubMed: 17904915]
16. Lund JL, Sturmer T, Porter CQ, et al. Thiazolidinedione use and ulcerative colitis-related flares: an
exploratory analysis of administrative data. Inflamm Bowel Dis. 2011; 17:787–94. [PubMed:
20848530]
17. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-
CM and ICD-10 administrative data. Med Care. 2005; 43:1130–9. [PubMed: 16224307]
18. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM
administrative databases. J Clin Epidemiol. 1992; 45:613–9. [PubMed: 1607900]
19. Radisic M, Lattes R, Chapman JF, et al. Risk factors for Pneumocystis carinii pneumonia in kidney
transplant recipients: a case-control study. Transpl Infect Dis. 2003; 5:84–93. [PubMed:
12974789]
20. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired
immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc.
1996; 71:5–13. [PubMed: 8538233]
21. Gilroy SA, Bennett NJ. Pneumocystis pneumonia. Semin Respir Crit Care Med. 2011; 32:775–82.
[PubMed: 22167405]
22. Phipps LM, Chen SC, Kable K, et al. Nosocomial Pneumocystis jirovecii Pneumonia: Lessons
From a Cluster in Kidney Transplant Recipients. Transplantation. 2011; 92:1327–34. [PubMed:
22129760]
23. Husni RN, Gordon SM, Longworth DL, et al. Cytomegalovirus infection is a risk factor for
invasive aspergillosis in lung transplant recipients. Clin Infect Dis. 1998; 26:753–5. [PubMed:
9524855]
24. Fishman JA. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin
Infect Dis. 2001; 33:1397–405. [PubMed: 11565082]
25. Martin SI, Fishman JA. Pneumocystis pneumonia in solid organ transplant recipients. Am J
Transplant. 2009; 9 (Suppl 4):S227–33. [PubMed: 20070684]
26. Lawrance IC, Radford-Smith GL, Bampton PA, et al. Serious infections in patients with
inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and
New Zealand experience. J Gastroenterol Hepatol. 2010; 25:1732–8. [PubMed: 21039834]
27. Herrinton LJ, Liu L, Lafata JE, et al. Estimation of the period prevalence of inflammatory bowel
disease among nine health plans using computerized diagnoses and outpatient pharmacy
dispensings. Inflamm Bowel Dis. 2007; 13:451–61. [PubMed: 17219403]
Long et al. Page 8














Incidence of pneumocystis jiroveci pneumonia (PCP) in inflammatory bowel disease (IBD)
and non-IBD populations
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Medications and hospitalizations in the 60 days prior to pneumocystis jiroveci pneumonia
(PCP) diagnosis in 38 patients with inflammatory bowel disease
In hospital: total duration and timing of hospitalized days prior to PCP diagnosis
Steroids: date where prescriptions filled (any dose or days supply) for corticosteroids
5-ASA: date where prescriptions filled (any dose or days supply) for 5-aminosalicylic acid
medications
AZA/6mp: data where prescriptions filled (any dose or days supply) for thiopurine
medications (azathioprine, mercaptopurine)
Tacrolimus: date where prescriptions filled (any dose or days supply) for tacrolimus
Humira/remicade: data where prescriptions filled (any dose or days supply) for infliximab
(remicade) or adalimumab (humira)
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